1.18 mill. €
% Year 2014
BIONATURIS (BIOORGANIC R.S.) D2014-MARZO
GVC Gaesco Beka, S.V., S.A.
IMPULSA CAPITAL S.L.
ERNST & YOUNG S.L.
AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA
|2014 until 25/03|
Period Close Price
Period Last Price
Period High Price
Period Low Price
Bionaturis is a biotechnology-based group offering premium solutions for human and animal health applications. The Biotech Group comprises 4 companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific LTD) and 2 subsidiaries (BNT China Biosciences and Biobide USA) located in three different continents, being worldwide references in their markets.
The matrix company of the Group, Bionaturis -Jerez de la Frontera, Cadiz-, is devoted to Animal Health, where is positioned as a partner of choice to bring high profitable products and services to the market place. By a B2B business model Bionaturis co-develops best-in-class prescription and non-prescription products for food production animals (FPAs) and pets. Cutting-edge antigens, probiotics and feed additives, among others, are part of the broad portfolio of products to meet the main needs of a steady growing sector.
Biobide -San Sebastian- is a preclinical CRO (Contract Research Organization) worldwide leader in the use of zebrafish as animal model for efficacy and toxicity assays for the Pharma, cosmetic, nutraceutical, agri-food, and environmental sectors.
ZIP Solutions –Barcelona- is a leading company in bioprocess having a relevant portfolio of international patents around its two main assets: Splittera and Zera Vaccines (subunit 2.0 and DNA vaccines). Its business model is based on the license of its proprietary systems to tier 1 companies in the sector.
The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at firstname.lastname@example.org.
What is MaB
Financing for companies
MaB for investors
News and Publications